These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 1465596)

  • 1. [Hyperkalemia during prolonged use of angiotensin II-converting enzyme inhibitors in end-stage renal insufficiency].
    Mooser V; Fellay G; Regamey C
    Schweiz Med Wochenschr; 1992 Dec; 122(50):1927-9. PubMed ID: 1465596
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effects of angiotensin converting enzyme inhibitors on potassium homeostasis in dialysis patients with and without residual renal function.
    Garthwaite E; Bhandari S
    Artif Organs; 2009 Aug; 33(8):641-7. PubMed ID: 19624582
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Use of angiotensin-converting enzyme inhibitors in chronic kidney insufficiency].
    Kutyrina IM; Lifshits NL; Rogov VA; Kamyshova ES; Shvetsov MIu; Okonova EB; Androsova SO; Martynov SA; Miroshnichenko NG; Gerasimenko OI
    Ter Arkh; 2002; 74(6):34-9. PubMed ID: 12136480
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum concentration of potassium in chronic heart failure patients administered spironolactone plus furosemide and either enalapril maleate, losartan potassium or candesartan cilexetil.
    Saito M; Takada M; Hirooka K; Isobe F; Yasumura Y
    J Clin Pharm Ther; 2005 Dec; 30(6):603-10. PubMed ID: 16336294
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of an ACE inhibitor or angiotensin receptor blocker on potassium in CAPD patients.
    Phakdeekitcharoen B; Leelasa-nguan P
    Am J Kidney Dis; 2004 Oct; 44(4):738-46. PubMed ID: 15384026
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ramipril and risk of hyperkalemia in chronic hemodialysis patients.
    Krajina-Andricević M; Zibar L; Juras K; Goll-Barić S; Barbić J
    Coll Antropol; 2011 Jun; 35(2):537-42. PubMed ID: 21755729
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [TBL] [Abstract][Full Text] [Related]  

  • 9. No impact of hyperkalaemia with renin-angiotensin system blockades in maintenance haemodialysis patients.
    Han SW; Won YW; Yi JH; Kim HJ
    Nephrol Dial Transplant; 2007 Apr; 22(4):1150-5. PubMed ID: 17255126
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum potassium in stage 5 CKD patients on their first presentation in a dialysis service of a county hospital in western Romania.
    Gluhovschi G; Mateş A; Gluhovschi C; Golea O; Gădălean F; Somai M; Ene I; Petrica L; Velciov S
    Rom J Intern Med; 2014; 52(1):30-8. PubMed ID: 25000676
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tissue renin angiotensin systems: theoretical implications for the development of hyperkalemia using angiotensin-converting enzyme inhibitors.
    Schlueter W; Keilani T; Batlle DC
    Am J Med Sci; 1994 Feb; 307 Suppl 1():S81-6. PubMed ID: 8141171
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of angiotensin-converting enzyme inhibitors in patients with heart failure and renal insufficiency: how concerned should we be by the rise in serum creatinine?
    Ahmed A
    J Am Geriatr Soc; 2002 Jul; 50(7):1297-300. PubMed ID: 12133029
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety of the combination of valsartan and benazepril in patients with chronic renal disease. European Group for the Investigation of Valsartan in Chronic Renal Disease.
    Ruilope LM; Aldigier JC; Ponticelli C; Oddou-Stock P; Botteri F; Mann JF
    J Hypertens; 2000 Jan; 18(1):89-95. PubMed ID: 10678548
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence of hyperkalemia among hemodialysis patients in Egypt.
    Khedr E; Abdelwhab S; El-Sharkawy M; Ali M; El Said K
    Ren Fail; 2009; 31(10):891-8. PubMed ID: 20030523
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inducing hyperkalemia by converting enzyme inhibitors and heparin.
    Durand D; Ader JL; Rey JP; Tran-Van T; Lloveras JJ; Bernadet P; Suc JM
    Kidney Int Suppl; 1988 Sep; 25():S196-7. PubMed ID: 3184611
    [No Abstract]   [Full Text] [Related]  

  • 16. Renin-angiotensin system blockade is not associated with hyperkalemia in chronic hemodialysis patients.
    Lin HH; Yang YF; Chang JK; Ting IW; Kuo HL; Wang IK; Huang CC
    Ren Fail; 2009; 31(10):942-5. PubMed ID: 20030530
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Dangerous hyperkalemia as sequelae of new treatment strategies of heart failure].
    Fuster D; Frey FJ; Ferrari P
    Praxis (Bern 1994); 2000 Dec; 89(49):2073-6. PubMed ID: 11190849
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of Renin-Angiotensin Aldosterone System Inhibition on Serum Potassium Levels among Peritoneal Dialysis Patients.
    Ribeiro SC; Figueiredo AE; Barretti P; Pecoits-Filho R; de Moraes TP;
    Am J Nephrol; 2017; 46(2):150-155. PubMed ID: 28738355
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A propensity score analysis of the impact of angiotensin-converting enzyme inhibitors on long-term survival of older adults with heart failure and perceived contraindications.
    Ahmed A; Centor RM; Weaver MT; Perry GJ
    Am Heart J; 2005 Apr; 149(4):737-43. PubMed ID: 15990761
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term renoprotective effect of combination therapy with prostaglandin E1 and angiotensin-converting enzyme inhibitor in patients with chronic renal failure.
    Nakayama Y; Nonoguchi H; Kiyama S; Kohda Y; Inoue T; Tomita K
    Hypertens Res; 2005 Sep; 28(9):733-9. PubMed ID: 16419646
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.